Video: Anti-Idiotypic antibodies for development of CAR T cell therapies
Interview with Michael Schwenkert, Bio-Rad Laboratories, on best practices for the characterisation and quality control of anti-idiotypic antibodies for bioanalysis.
List view / Grid view
Interview with Michael Schwenkert, Bio-Rad Laboratories, on best practices for the characterisation and quality control of anti-idiotypic antibodies for bioanalysis.
The rising number of biologics approved for therapeutic use has placed an emphasis on safe and efficient production lines. Here, Drug Target Review’s Editor Victoria Rees considers why biotherapeutic development is likely to prompt significant growth for the cell line market in the next decade.
Read this bulletin to learn about a Bio-Rad study where they developed and tested a 16-parameter flow cytometry panel applicable to the interrogation of a range of biologically relevant markers of T cell activation.
Do you know how much time your lab spends on pipetting tasks daily? If not you can easily find out. Just answer four simple questions, then Flow Robotics' calculator can give you a full report on how your lab is doing in minutes.
25 March 2022 | By Bruker Daltonics
Watch our free on-demand webinar to discover how the new timsTOF MPP product solution, with its dedicated MALDI PharmaPulse 2023 HTS software suite, improves data quality and accelerates high-throughput screening in drug discovery.
Urea cycle disorders affect the liver’s ability to excrete urea from the body. To test potential therapeutics requires an accurate model – a hurdle that has now been successfully navigated thanks to a team of researchers in Switzerland.
Three-dimensional (3D) biopsy culture models could save the drug discovery industry time and money. In this article, Johanna Niklander, University of Helsinki and Medical University of Graz, and Dr Beate Rinner, Medical University of Graz, outline a recent study they took part in, investigating long-term 3D tissue cultures from human…
In this ebook, find an article on 3D tissue cultures from biopsy samples to evaluate the preservation of tissue-typical protein expressions as well as a piece on a new process analytical technology (PAT) system to assess N-glycosylation during upstream cell culture bioprocessing.
Here, we round up some of the key takeaways from the expert panel discussions at the Cell & Gene Therapy Advancements Online Summit.
All mice infected with anthrax spores were completely protected after treatment with a pegylated enzyme known as PEG-CapD-CPS334C.
Watch this exclusive interview with Professor Ann Ager, Cardiff University, to discover how CAR T cells could be targeted against solid tumours.
Synthetic biology processes can be useful to therapeutic development, diagnostics and vaccine advancement. Drug Target Review’s Victoria Rees spoke with Dr Jim Collins, Termeer Professor of Medical Engineering & Science at MIT and Founding Core Faculty & Lead, Living Cellular Devices at the Wyss Institute at Harvard University, to explore…
Stanford researchers have developed a multi-purpose “mini” CRISPR system, called CasMINI, that may be easier to deliver into human cells.
Evaluation of neurotoxicity effects is an active area of investigation in drug discovery and disease modeling.
This whitepaper describes several live-cell phenotypic analyses suitable for the characterisation of astroglia cells.